Active ingredient
Orforglipron: FDA Status, Uses, Safety and Cost
Single receptor target (GLP-1)
Not FDA approved
Orforglipron is an investigational compound. It has not been approved by the FDA for any use, its safety and effectiveness have not been established, and it cannot legally be sold or dispensed as a medication in the United States. There is no legitimate way to purchase it. This page is informational only.
What Orforglipron is
Orforglipron is an investigational oral (pill) GLP-1 medication being developed by Eli Lilly. It is NOT FDA approved. Unlike existing GLP-1 drugs, which are peptides, orforglipron is a small molecule designed to be taken as a daily pill without food and water restrictions. Late-stage clinical trials have been conducted and the company has publicly discussed regulatory submissions — check primary sources for the current status, which may have changed since this page was last reviewed.
Key facts
| Generic (active ingredient) | Orforglipron |
|---|---|
| Brand names | None — investigational compound |
| Drug class | Oral small-molecule GLP-1 receptor agonist |
| Manufacturer | Eli Lilly and Company (developer) |
| FDA status | InvestigationalNot FDA approved |
| Administration | Oral tablet (in clinical trials) |
| Frequency | Once daily (in clinical trials) |
| Approval date | Not applicable — not FDA approved |
| Prescription required | Yes |
| Official label | None — no approved product exists |
What Orforglipron is approved for
None. Orforglipron has no FDA-approved indications because it is not an approved drug. Claims that it is approved, or that it can be legally prescribed or sold, are false.
How Orforglipron works
Orforglipron is designed to activate the GLP-1 receptor like injectable GLP-1 drugs, but as a non-peptide oral molecule. Its efficacy and safety have not been established by the FDA.
Administration
Orforglipron is given by oral tablet (in clinical trials), once daily (in clinical trials).
We do not publish dosing guidance
Dose selection, titration schedules, and what to do about a missed dose are individual clinical decisions. Follow the instructions from your prescriber and the official prescribing information — never a website.
Important safety information
There is no FDA-approved labeling for Orforglipron, so there is no established list of warnings, contraindications, or adverse reactions. Absence of a warning here does not mean the compound is safe — it means safety has not been established.
Cost and access
- Not available by prescription — it is not an approved drug as of this page’s last review.
- Anything sold online as "orforglipron" is an unapproved product; no licensed U.S. pharmacy can legally dispense it.
- The only legitimate access is a registered clinical trial (see ClinicalTrials.gov).
Why we don't publish a price
List prices, savings-card amounts, and self-pay offers change frequently and vary by pharmacy, plan, and location. Any figure we printed would be wrong for many readers and stale within weeks. See our cost guide for how to get an accurate number for your own situation.
Insurance considerations
- Not applicable — investigational drugs are not covered products.
More detail: how insurance coverage works for weight-loss medication.
Frequently asked questions
- Is orforglipron FDA approved?
- No — as of this page’s last review, orforglipron is investigational and not FDA approved. Regulatory status can change; check FDA sources for the latest.
- Will orforglipron be a pill?
- It is being developed as a once-daily oral tablet. If approved, it would be among the first small-molecule oral GLP-1 medications — but approval, labeling, and availability are not established until the FDA acts.
Related guides
Sources
- ClinicalTrials.gov — orforglipron studies — NIH. Link last verified August 12, 2026.
- Eli Lilly newsroom — Manufacturer. Link last verified August 12, 2026.
Not medical advice. WeightLossDrugsGuide is an independent educational publisher. We are not a pharmacy, a medical provider, or a telehealth clinic, and we do not provide personalized medical recommendations or dosing guidance. Information here summarizes official FDA labeling and other primary sources and may not reflect the most recent changes. Always talk with a licensed clinician about your own situation, and read the full prescribing information for any medication.